Importance of antifungal drug-resistance: clinical significance and need for novel therapy

Bibliography

• CHIMELLI L, MAHLER-ARAUJO MB: Fungal infections. Brain Pathol. (1997) 7:613–627.
   PubMed Web of Science ®Google Scholar
• ••This is an excellent review of both opportunistic and patho-genic fungi and the diseases they cause in the central nerv-ous system.
   Google Scholar
• DIXON DM, MCNEIL MM, COHEN ML eta].: Fungal infec- tions: a growing threat. Public Health Rep. (1996) 111:226–235.
   Google Scholar
• ••These authors address the problematic increase in incidenceof fungal infections to recently emerging, uncommon patho-gens, as well as unknown fungal pathogens in the immuno-suppressed patient population.
   Google Scholar
• GOA KL, BARRADELL LB: Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. [Published erratum appears in Drugs 1996 March 51(3):505[. Drugs (1995) 50:658–690.
   Google Scholar
• BODEY GP: Azole antifungal agents. C]in. Infect. Dis. (1992) 14 (Suppl. 0:161–169.
   Google Scholar
• KAUFFMAN CA: Role of azoles in antifungal therapy. Clin. Infect. Dis. (1996) 22 (Suppl. 2):148–153.
   Google Scholar
• •This review provides a detailed discussion on the therapeu-tic use of the azoles, itraconazole and fluconazole.
   Google Scholar
• WINSTON DJ, CHANDRASEKAR PH, LAZARUS HM et al.: Fluconazole prophylaxis of fungal infections in pa-tients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial [see comments]. Ann. Intern. Med. (1993) 118:495–503.
   Google Scholar
• WALSH TJ, LEE JW: Prevention of invasive fungal infec-tions in patients with neoplastic disease. Clin. Infect. Dis. (1993) 17 (Suppl. 2):468–480.
   Google Scholar
• ••This article provides a thorough review of methods used,and possible future alternatives, to prevent invasive fungal infections in granulocytopenic patients resulting from treat-ment of neoplasms.
   Google Scholar
• SAMARANAYAKE YH, SAMARANAYAKE LP: Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J. Med. Microbiol. (1994) 41:295–310.
   PubMed Web of Science ®Google Scholar
• SANCHEZ V, VAZQUEZ JA, BARTH-JONES D eta].: Epide-miology of nosocomial acquisition of Candida lusita-niae. j Clin. Microbiol. (1992) 30:3005–3008.
   Web of Science ®Google Scholar
• OLEINIK EM, DELLA-LATTA P, RINALDI MG et al.: Can-dida lusitaniae osteomyelitis in a premature infant. Am. J. Perinatol. (1993) 10:313–315.
   PubMed Web of Science ®Google Scholar
• HAZEN KC: New and emerging yeast pathogens. Clin. Microbiol. Rev. (1995) 8:462–478.
   PubMed Web of Science ®Google Scholar
• ••An excellent overview including the identification of infec-tions caused by new and emerging yeast pathogens.
   Google Scholar
• BLINKHORN RJ, ADELSTEIN D, SPAGNUOLO PJ: Emer-gence of a new opportunistic pathogen, Candida lusi-taniae. j Clin. Microbiol. (1989) 27:236–240.
   PubMed Web of Science ®Google Scholar
• MARTINS MD, REX JH: Resistance to antifungal agents in the critical care setting: problems and perspectives. New Horiz. (1996) 4:338–344.
   PubMedGoogle Scholar
• PFALLER MA: Nosocomial candidiasis: emerging spe-cies, reservoirs, and modes of transmission. ain. In-fect. Dis. (1996) 22 (Suppl. 2):S89–94.
   Google Scholar
• ••A comprehensive survey of the importance of non-albicansCandida as agents of infections, including the potential res-ervoir modes of transmission, and resistance.
   Google Scholar
• VISCOLI C, CASTAGNOLA E, MACHETTI M: Antifungal treatment in patients with cancer. J. Intern. Med. Suppl. (1997) 740:89–94.
   PubMedGoogle Scholar
• WHELAN WL: The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit. Rev. Microbiol. (1987) 15:45–56.
   PubMed Web of Science ®Google Scholar
• BRANDT ME, PFALLER MA, HAJJEH RA et al.: Molecular subtypes and antifungal susceptibilities of serial Cryp-tococcus neoformans isolates in human immunodefi-ciency virus-associated cryptococcosis. Cryptococcal Disease Active Surveillance Group. J. Infect. Dis. (1996) 174:812–820.
   PubMed Web of Science ®Google Scholar
• BOZZETTE SA, LARSEN RA, CHIU J et al.: Fluconazoletreatment of persistent Cryptococcus neoformans prostatic infection in AIDS. Ann. Intern. Med. (1991) 115:285–286.
   PubMed Web of Science ®Google Scholar
• LARSEN RA, BOZZETTE S, MCCUTCHAN JA eta].: Persis-tent Cryptococcus neoformans infection of the pros-tate after successful treatment of meningitis. California Collaborative Treatment Group [see com-ments]. Ann. Intern. Med. (1989) 111:125–128.
   Google Scholar
• KAUFFMAN CA, SHEA MJ, FRAME PT: Invasive fungal in-fections in patients with chronic mucocutaneous can-didiasis. Arch. Intern. Med. (1981) 141:1076–1079.
   PubMed Web of Science ®Google Scholar
• PEETERMANS W, BOBBAERS H, VERHAEGEN J et al.: Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient. Acta Clin. Belg. (1993) 48:405–409.
   PubMed Web of Science ®Google Scholar
• REX JH, PFALLER MA, GALGIANI JN eta].: Development of interpretive breakpoints for antifungal susceptibil-ity testing: conceptual framework and analysis of in vitro-in vivocorrelation data for fluconazole, itracona-zole, and candida infections. Subcommittee on Anti-fungal Susceptibility Testing of the National Committee for Clinical laboratory Standards [see com-ments]. Clin. Infect. Dis. (1997) 24:235–247.
   Google Scholar
• ••An outstanding explanation of the interpretations of antifun-gal susceptibility test results and the attempt to correlate these data with clinical outcomes in order to choose inter-pretive criteria.
   Google Scholar
• BERENGUER J, FERNANDEZ-BACA V, SANCHEZ R eta].: In vitro activity of amphotericin B, flucytosine and flu-conazole against yeasts causing bloodstream infec-tions. Eur. j Clin. Microbiol. Infect. Dis. (1995) 14:362–365.
   Google Scholar
• JOSEPH-HORNET, HOLLOMON D, LOEFFLER RS eta].: Al-tered P450 activity associated with direct selection for fungal azole resistance. FEBS Lett. (1995) 374:174–178.
   Google Scholar
• LOFFLER J, KELLY SL, HEBART H eta].: Molecular analy-sis of cyp51 from fluconazole-resistant Candida albi-cans strains. FEMS Microbiol. Lett. (1997) 151 :263–268.
   Google Scholar
• SANGLARD D, KUCHLER K, ISCHER F eta].: Mechanisms of resistance to azole antifungal agents in Candida al-bicans isolates from AIDS patients involve specific multidrug transporters. Andmicrob. Agents Chemother. (1995) 39:2378–2386.
   Google Scholar
• ••A pivotal report in which the investigators addressed the is-sue of azole resistance in clinical isolates on a molecular ba-sis and observed that specific efflux pumps could result in azole resistance.
   Google Scholar
• HITCHCOCK CA, RUSSELL NJ, BARRETT-BEE KJ: Sterols inCandida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4. Crit. Rev. Microbiol. (1987) 15:111–115.
   Google Scholar
• ALBERTSON GD, NIIMI M, CANNON RD eta].: Multiple ef-flux mechanisms are involved in Candida albicans flu-conazole resistance. Antimicrob. Agents Chemother. (1996) 40:2835–2841.
   Google Scholar
• ••The data from these studies indicate that fluconazole gainsentry into C. albicans cells by facilitated diffusion and that fluconazole resistance may involve energy-dependent ef-flux, which is associated with increased expression of Benr and/or Cdrl.
   Google Scholar
• CLARK FS, PARKINSON T, HITCHCOCK CA eta].: Correla-tion between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob. Agents Chemother. (1996) 40:419–425.
   Google Scholar
• GOLDWAY M, TEFF D, SCHMIDT R eta].: Multidrug resis-tance in Candida albicans: disruption of the BENr gene. Antimicrob. Agents Chemother. (1995) 39:422–426.
   PubMed Web of Science ®Google Scholar
• JOSEPH-HORNE T, HOLLOMON DW: Molecular mecha-nisms of azole resistance in fungi. FEMS Microbiol. Let. (1997) 149:141–149.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of azole resistance at the molecularlevel
   Google Scholar
• LAMB DC, KELLY DE, MANNING NJ eta].: Reduced intra-cellular accumulation of azole antifungal results in re-sistance in Candida albicans isolate NCPF 3363. FEMS Microbiol. Lett. (1997) 147:189–193.
   Google Scholar
• PARKINSON T, FALCONER DJ, HITCHCOCK CA: flucona-zole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob. Agents Chemother. (1995) 39:1696–1699.
   PubMed Web of Science ®Google Scholar
• WHITE TC: Increased mRNA levels of ERG16, CDR, andMDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. (1997) 41:1482–1487.
   PubMed Web of Science ®Google Scholar
• DENNING DW, VENKATESWARLU K, OAKLEY KL et al.: Itr aeon azole resistance in Aspergillus fumigatus. Anti-microb. Agents Chemother. (1997) 41:1364–1368.
   PubMed Web of Science ®Google Scholar
• WHEAT J, MARICHAL P, VANDEN BOSSCHE H et al.: Hy-pothesis on the mechanism of resistance to flucona-zole in Histoplasma capsulatum. Antimicrob. Agents Chemother. (1997) 41:410–414.
   PubMedGoogle Scholar
• MARTINEZ-SUAREZ JV, RODRIGUEZ-TUDELA JL: [Anti-fungal resistance in opportunistic pathogenic fungi (I). Polyenes and fluorocytosine]. Enferm. Infec. Micro-biol. Clin. (1996) 14:384–389.
   PubMedGoogle Scholar
• JOSEPH-HORNE T, HOLLOMON D, LOEFFLER RS et al.: Cross-resistance to polyene and azole drugs in Crypto-coccus neoformans. Antimicrob. Agents Chemother. (1995) 39:1526–1529.
   PubMed Web of Science ®Google Scholar
• RUSSELL NJ, KERRIDGE D, BOKOR JT: Sterol metabolism during germination of conidia of Aspergillus fumiga-tus. J. Gen. Microbiol. (1977) 101:197–206.
   PubMedGoogle Scholar
• WINGARD JR: Infections due to resistant Candida spe-cies in patients with cancer who are receiving chemo-therapy. Clin. Infect. Dis. (1994) 19 (Suppl. 0:49–53.
   Google Scholar
• KELLY SL, LAMB DC, KELLY DE eta].: Resistance to flu-conazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defec-tive sterol delta 5,6-desaturation. FEBS Lett. (1997) 400:80–82.
   Google Scholar
• DICK JD, MERZ WG, SARAL R: Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob. Agents Chemother. (1980) 18:158–163.
   PubMed Web of Science ®Google Scholar
• JOSEPH-HORNET, MANNING N, HOLOMAN D eta].: Non-sterol related resistance in Ustilago maydis to the polyene antifungals, amphotericin B and nystatin. Phytochemistry (1996) 42:637–639.
   Google Scholar
• AMPEL NM: Emerging disease issues and fungal patho-gens associated with HIV infection. Emerg. Infect. Dis (1996) 2:109–116.
   PubMed Web of Science ®Google Scholar
• ••A practical overview of the issues involved in the manage-ment of fungal infections, therapy and prevention of fungal disease in HIV-1 infected individuals.
   Google Scholar
• KRCMERY V, Jr.: Emerging fungal infections in cancer patients. J. Hosp. Infect. (1996) 33:109–117.
   PubMed Web of Science ®Google Scholar
• MITCHELL TG, PERFECT JR: Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoforrnans. Clin. Microbiol. Rev. (1995) 8:515–548.
   PubMed Web of Science ®Google Scholar
• LEE YP, GOLDMAN M: The role of azole antifungal agents for systemic antifungal therapy. Deve. Clin. Med. (1997) 64 :99–106.
   Google Scholar
• KLASTERSKY J: Prevention of infection in n eutr op enic cancer patients. Curr. Opin. Oncol. (1996) 8:270–278.
   PubMedGoogle Scholar
• CASTAGNOLA E, BUCCI B, MONTINARO E et al.: Fungal infections in patients undergoing bone marrow trans-plantation: an approach to a rational management protocol. Bone Marrow Transplant. (1996) 18 (Suppl. 2):97–106.
   Google Scholar
• PHILPOTT-HOWARD JN, WADE JJ, MUFTI GJ et al.: Ran-domized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in pa-tients at risk of neutropenia. Multicentre Study Group. Antimicrob. Chemother. (1993) 31 :973–984.
   PubMed Web of Science ®Google Scholar
• PINNER RW, HAJJEH RA, POWDERLY WG: Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin. Infect. Dis. (1995) 21 (Suppl. 0:103–107.
   Google Scholar
• RICHARDSON MD: Opportunistic and pathogenic fungi. J. Antimicrob. Chemother. (1991) 28 (Suppl A):1–11.
   Google Scholar
• PFALLER MA: Epidemiology and control of fungal infec-tions. Clin. Infect. Dis. (1994) 19 (Suppl. 0:8–13.
   Google Scholar
• •Excellent review of the epidemiology of fungal infections and the use of this critical information in controlling and pre-venting disease.
   Google Scholar
• PFALLER MA: Epidemiology of candidiasis. J. Hosp. In-fect. (1995) 30 (Suppl.):329–338.
   Google Scholar
• MAHAYNI R, VAZQUEZ JA, ZERVOS MJ:Nosocomial can-didiasis: epidemiology and drug resistance. Infect. Agents Dis. (1995) 4:248–253.
   PubMedGoogle Scholar
• KHOO SH, BOND J, DENNING DW: Administering am-ph o tericin B - a practical approach. J Antimicrob. Che-mother. (1994) 33:203–213.
   PubMed Web of Science ®Google Scholar
• KAUFFMAN CA, CARVER PL: Use of azoles for systemic antifungal therapy. Adv. Pharmacol. (1997) 39:143–189.
   PubMedGoogle Scholar
• MARR KA, WHITE TC, VAN BURIK JA eta].: Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing mar-row transplantation [In Process Citation]. Clin. Infect. Dis. (1997) 25:908–910.
   Google Scholar
• MEDOFF G: New challenges to the therapy of systemic fungal infections. Trans. Am. Clin. Climatol. Assoc. (1995) 107:146–157..
   Google Scholar
• ODDS FC: Resistance of yeasts to azole-derivative anti-fungals. j Antimicrob. Chemother. (1993) 31:463–471.
   PubMed Web of Science ®Google Scholar
• MCCREARY C, BERGIN C, PILKINGTON R eta].: Clinical parameters associated with recalcitrant oral candido-sis in HIVinfection: a preliminary study. Int. J. STD AIDS (1995) 6:204–207.
   Google Scholar
• POWDERLY WG: Resistant candidiasis. AIDS Res. Hum.Retroviruses (1994) 10:925–929.
   PubMed Web of Science ®Google Scholar
• WHITE A, GOETZ MB: Azole-resistant Candida albi-cans report of two cases of resistance to fluconazole and review. Clin. Infect. Dis. (1994) 19:687–692.
   PubMed Web of Science ®Google Scholar
• LYNCH ME, SOBEL JD, FIDEL PL, Jr.: Role of antifungal drug resistance in the pathogenesis of recurrent vulvo-vaginal candidiasis. J. Med. Vet. Mycol. (1996) 34:337–339.
   Google Scholar
• WHEAT L, MAWHINNEY S, HAFNER R eta].: fluconazole treatment for histoplasmosis in AIDS: prospective multicenter non-comparative trial. Abstracts of the 34th ICAAC (1994).
   Google Scholar
• JOSEPH-HORNE T, LOEFFLER RS, HOLLOMON DW eta].: Arnphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J. Med. Vet. Mycol. (1996) 34:223–225.
   Google Scholar
• VENKATESWARLU K, TAYLOR M, MANNING NJ eta].: Flu-conazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41:748–751.
   Google Scholar
• ALEXANDER BD, PERFECT JR: Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches [In Process Citation]. Drugs (1997) 54:657–678.
   Google Scholar
• ••A thorough analysis of the causes and mechanisms of resis-tance emergence and speculation on the potential strategies to combat and overcome resistance in the future.
   Google Scholar
• BENNETT JE: Chemotherapy of systemic mycoses (sec-ond of two parts). New Engl. J. Med. (1974) 290:320–323.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT RY: Antifungal drugs. J. Antimicrob. Che-mother. (1975) 1:141–162.
   PubMedGoogle Scholar
• DEMURI GP, HOSTETTER MK: Resistance to antifungal agents. Pediatr. Clin. North Am. (1995) 42:665–685.
   PubMed Web of Science ®Google Scholar
• ERNEST JM: Topical antifungal agents. Obstet. Gynecol. Clin. North Am. (1992) 19:587–607.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR: Future directions of antifungal chemo-therapy [see comments]. Clin. Infect. Dis. (1992) 14 (Suppl. 1) :170–181.
   Google Scholar
• GRAYBILL JR: Antifungal drugs and resistance. Adv. Exp. Med. Biol. (1995) 390:217–234.
   PubMedGoogle Scholar
• GRAYBILL JR: The future of antifungal therapy. Clin. In-fect. Dis. (1996) 22 (Suppl. 2):166–178. Critical review of the possibilities of combining antifungal therapy with immunomodulation for the management of fungal infections.
   Google Scholar
• HAY RJ: Overview of the treatment of disseminated fungal infections. J. Antimicrob. Chemother. (1991) 28 (Suppl. B):17–25.
   Google Scholar
• IWATA K: Drug resistance in human pathogenic fungi. Eur. Epidemiol. (1992) 8:407–421.
   PubMed Web of Science ®Google Scholar
• KLASTERSKY J: Prevention and therapy of fungal infec-tions in cancer patients. A review of recently pub-lished information [see comments]. Support Care Cancer (1995) 3:393–401.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI GS, MEDOFF G: Antifungal agents: recent developments. Ann. Rev. Microbiol. (1977) 31:291–308.
   PubMed Web of Science ®Google Scholar
• MEDOFF G, KOBAYASHI GS: Strategies in the treatment of systemic fungal infections. New Engl. J Med. (1980) 302:145–155.
   PubMed Web of Science ®Google Scholar
• MEYER RD: Current role of therapy with amphotericin B. Clin. Infect. Dis. (1992) 14 (Suppl. 0:154–160.
   Google Scholar
• SLAVOSKI LA, TUNKEL AR: Therapy of fungal meningi-tis. Clin. Neuropharmacol. (1995) 18:95–112.
   PubMedGoogle Scholar
• TORRES-RODRIGUEZ JM: New topical antifungal drugs. Arch. Med. Res. (1993) 24:371–375.
   PubMedGoogle Scholar
• VIVIANI MA: Combinations of antimycotics. G. Ital. Chemioter. (1984) 31:1–6.
   PubMedGoogle Scholar
• GEORGOPAPADAKOU NH, WALSH Ti Human mycoses: drugs and targets for emerging pathogens. Science (1994) 264:371–373.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH, WALSH TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. (1996) 40:279–291.
   PubMed Web of Science ®Google Scholar
• MARICHAL P, VANDEN BOSSCHE H: Mechanisms of re-sistance to azole antifungals. Acta Biochim. Pol. (1995) 42:509–516.
   PubMed Web of Science ®Google Scholar
• BORGERS M: Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Rev. Infect. Dis. (1980) 2:520–534.
   PubMedGoogle Scholar
• BENNET JE: Flucytosine. Ann. Intern. Med. (1977) 86:319–321.
   PubMedGoogle Scholar
• KERRIDGE D: Mode of action of clinically important an-tifungal drugs. Adv. Microb. Physiol. (1986) 27:1–72.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, WARNOCK DW, DUPONT B eta].: Mechanisms and clinical impact of antifungal drug re-sistance. J. Med. Vet. Mycol. (1994) 32 (Suppl. 1):189–202.
   Google Scholar
• LYMAN CA, WALSH TJ: Systemically administered anti-fungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 44:9–35.
   Google Scholar
• ••Outstanding review of the pharmacokinetics, mechanismsof action, and toxicities of systemic antifungal agents.
   Google Scholar
• PERFECT JR, KLOTMAN ME, GILBERT CC et al.: Prophy-lactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. j In-fect. Dis. (1992) 165:891–897.
   PubMed Web of Science ®Google Scholar
• PERFECT JR, WRIGHT KA: Arnphotericin B lipid com-plex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. j Antimicrob. Chemother. (1994) 33:73–81.
   PubMed Web of Science ®Google Scholar
• GRANT SM, CLISSOLD SP: Fluconazole. A review of itspharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. [Published erratum appears in Drugs 1990:40(6):862]. Drugs (1990) 39:877–916.
   Google Scholar
• •A thorough review for the introduction of fluconazole, de-tailing its therapeutic usefulness in the treatment of fungal infections.
   Google Scholar
• MEUNIER F: Targeting fungi: a challenge. Ain. J. Med. (1995) 99:60S–67S.
   Google Scholar
• MEUNIER F: Future directions of antimycotic therapy. Mycoses (1994) 37 (Suppl. 2):77–82.
   Google Scholar
• KAUFFMAN CA, CARVER PL: Antifungal agents in the 1990s. Current status and future developments. Drugs (1997) 53:539–549.
   Google Scholar
• •Review of the current status of antifungal drugs with the em-phasis on future progress including improved delivery sys-tems, and new fungicidal agents, and new treatment options.
   Google Scholar
• CORMICAN MG, PFALLER MA: Epidemiology of can-didiasis. Compr. Ther. (1995) 21 :653–657.
   PubMedGoogle Scholar
• DESLAURIERS N, COTE L, MONTPLAISIR S eta].: Oral car-riage of Candida albicans in murine AIDS. Infect. Im-munol. (1997) 65:661–667.
   Google Scholar
• KLEPSER ME, ERNST EJ, PFALLER MA: Update on antifun-gal resistance. Trends Microbiol. (1997) 5:372–375.
   PubMedGoogle Scholar
• VANDEN BOSSCHE H, MARICHAL P, ODDS FC: Molecular mechanisms of drug resistance in fungi. Trends Micro-biol. (1994) 2:393–400.
   PubMedGoogle Scholar
• ••Excellent review on the molecular basis of antifungal resis-tance and relationship to clinical failures.
   Google Scholar
• FISHER-HOCH SP, HUTVVAGNER L: Opportunistic can-didiasis: an epidemic of the 1980s. Clin. Infect. Dis. (1995) 21:897–904.
   PubMed Web of Science ®Google Scholar
• BODEY GP: New fungal pathogens. Curr. Clin. Top. In-fect. Dis. (1997) 17:205–235.
   PubMedGoogle Scholar
• KUNOVA A, TRUPL J, SPANIK S et al.: Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989–1993: no association with the use of flu-conazole. Chemotherapy (1995) 41 :39–44.
   Google Scholar
• SOBEL JD: Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin. Infect. Dis. (1992) 14 (Suppl. 1):148–153.
   Google Scholar
• WEEMS JJ, Jr.: Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicro-bial susceptibility [see comments]. Clin. Infect. Dis. (1992) 14:756–766.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM I: Pulmonary infections after bone mar-row transplant. Semin. Respir. Infect. (1992) 7:132–138.
   PubMedGoogle Scholar
• BODEY GP: What's new in fungal infection in leukemic patients. Leuk. Lymphoma (1993) 11 (Suppl. 2):127–135.
   Google Scholar
• BOUTATI El, ANAISSIE EJ: Fusarium, a significant emerging pathogen in patients with hematologic ma-lignancy: ten years' experience at a cancer center and implications for management. Blood (1997) 90:999–1008.
   PubMed Web of Science ®Google Scholar
• BLAZAR BR, HURD DD, SNOVER DC eta].: Invasive Fusar-ium infections in bone marrow transplant recipients. Am. J. Med. (1984) 77:645–651.
   Google Scholar
• JUNE CH, BEATTY PG, SHULMAN HM eta].: Disseminated Fusarium moniliforme infection after allogeneic mar-row transplantation. South Med. J. (1986) 79:513–515.
   Google Scholar
• RABODONIRINA M, PIENS MA, MONIER MF eta].: Fusar-ium infections in immunocompromised patients: case reports and literature review. Eur. j Clin. Microbiol. In-fect. Dis. (1994) 13:152–161.
   Google Scholar
• MARTINO P, GASTALDI R, RACCAH R eta].: Clinical pat-terns of Fusarium infections in immunocompromised patients. J. Infect. (1994) 28 (Suppl. 1):7–15.
   Google Scholar
• VARTIVARIAN SE, ANAISSIE EJ, BODEY GP: Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis. (1993) 17 (Suppl. 2):5487–491.
   Google Scholar
• •Thorough review on the microbiology of emerging fungal pathogens and the issues in management of immunocom-promised patients with fungal infections.
   Google Scholar
• CLEMONS KV, HOMOLA ME, STEVENS DA: Activities of the triazole SCH51048 against Coccidioides immitis in vitro and in vivo. Antimicrob. Agents. Chemother. (1995) 39:1169–1172.
   PubMed Web of Science ®Google Scholar
• COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy [see comments]. New Engl. J. Med. (1994) 330:263–272.
   PubMed Web of Science ®Google Scholar
• GURNEY JW, CONCES DJ: Pulmonary histoplasmosis. Radiology (1996) 199:297–306.
   PubMed Web of Science ®Google Scholar
• JOHNSON P, SAROSI G: Current therapy of major fungal diseases of the lung. Infect. Dis. Clin. North Arm (1991) 5:635–645.
   PubMedGoogle Scholar
• ••Outstanding update on the use of amphotericin B includingits physicochemical properties, mechanism of action, as well as attempts to decrease its toxic effects to host cells and im-prove its therapeutic index uutstanaing upaate on tne use ot ampnotencm inciumngits physicochemical properties, mechanism of action, as well as attempts to decrease its toxic effects to host cells and im-prove its therapeutic index.
   Google Scholar
• ABU-SALAH KM: Arnphotericin B: an update. Br. J Bio-med. Sci. (1996) 53:122-133. ABU-SALAH KM: Arnphotericin B: an update. Br. J Bio-med. Sci. (1996) 53:122–133.
   Google Scholar
• DING JC, BAUER M, DIAMOND DM eta].: Effect of sever-ity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryp-tococcal meningitis. Antimicrob. Agents Chemother. (1997) 41:1589–1593.
   Google Scholar
• ZEIND CS, CLEVELAND KO, MENON M eta].: Cryptococ-cal meningitis in patients with the acquired immuno-deficiency syndrome. Pharmacotherapy (1996) 16:547–561.
   Google Scholar
• GRAYBILL JR, VAZQUEZ J, DAROUICHE RO et al.: Itra-conazole oral solution (IS) versus fluconazole (F) treatment of oropharyngeal candidiasis (0C). 35th In-terscience Conference on Antimicrobial Agents and Chemo-therapy (1995):1220.
   Google Scholar
• HAY RJ: Antifungal therapy of yeast infections. J Arm Acad. Dermatol. (1994) 31:S6–9.
   PubMed Web of Science ®Google Scholar
• VISCOLI C, CASTAGNOLA E, VAN LINT MT eta].: Flucona-zole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur. J Cancer (1996) 32A:814–820.
   Google Scholar
• DIEHL KB: Topical antifungal agents: an update. Arm Farm Physician (1996) 54:1687–1692.
   PubMed Web of Science ®Google Scholar
• •A discussion on the pros and cons of older and newer topi-cal antifungal agents.
   Google Scholar
• BIRNBAUM JE: Pharmacology of the allylamines. J. Arm Acad. Dermatol. (1990) 23:782–785.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH, BERTASSO A: Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob. Agents Chemother. (1992) 36:1779–1781.
   PubMed Web of Science ®Google Scholar
• RYDER NS: Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br. J Dermatol. (1992) 126 (Suppl. 39):2–7.
   Google Scholar
• VANDEN BOSSCHE H, MARICHAL P: Mode of action of anti-Candida drugs: focus on terconazole and other er-gosterol biosynthesis inhibitors. Arm J Obstet. Gynecol. (1991) 165:1193–1199.
   PubMed Web of Science ®Google Scholar
• KLASTERSKY J: Empiric treatment of infection during granulocytopenia. Ann. Oncol. (1990) 1:255–261.
   PubMed Web of Science ®Google Scholar
• DJEU JY: Cytokines and anti-fungal immunity. Adv. Exp. Med. Biol. (1992) 319:217–223.
   PubMedGoogle Scholar
• KULLBERG BJ, VAN T, WOUT JW: Cytokines in the treat-ment of fungal infections. Biotherapy (1994) 7:195–210.
   PubMedGoogle Scholar
• •Update on the use of cytokines having great potential to augment host immune status and as adjunct therapy of inva-sive mycoses.
   Google Scholar
• VAN DER MEER JW, VOGELS M, CURFS JH et al.: Interleukin-1 as a possible agent for treatment of infec-tion. Eur. j Clin. Microbiol. Infect. Dis. (1993) 12 (Suppl. 1): 73–77.
   Google Scholar
• FREIFELD AG: Infectious complications in the immu-nocompromised host. The antimicrobial armamen-tarium. Hematol. Oncol. Clin. North Am. (1993) 7:813–839.
   PubMedGoogle Scholar
• HOF H, KRETSCHMAR M: Rational use of antimycotics against yeast infections. Immun. Infekt. (1995) 23 :209–215.
   PubMedGoogle Scholar
• WALSH TJ, SCHIMPFF SC: Prevention of infection among patients with cancer. Eur. J Cancer Clin. Oncol. (1983) 19:1333–1344.
   PubMedGoogle Scholar
• SHARKEY PK, GRAYBILL JR, JOHNSON ES eta].: Amp ho-tericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in pa-tients with AIDS [see comments]. Clin. Infect. Dis. (1996) 22 :315–321.
   Google Scholar
• DROUHET E: Basic mechanisms of antifungal chemo-therapy. Mod. Treat. (1970) 7:539–564.
   PubMedGoogle Scholar
• ADLER-MOORE J: ArnBisome targeting to fungal infec-tions. Bone Marrow Transplant. (1994) 14 (Suppl. 5):53–7.
   Google Scholar
• HOLT RJ: Recent developments in antimycotic chemo-therapy. Infection (1974) 2:95–107.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, WILLEMSENS G, MARICHAL P: Anti-Candida drugs - the biochemical basis for their activity. Crit. Rev. Microbiol. (1987) 15:57–72.
   PubMed Web of Science ®Google Scholar
• DENNING DW, BAILY GG, HOOD SV:Azole resistance in Candida. Eur. j Clin. Microbiol. Infect. Dis. (1997) 16:261–280.
   PubMed Web of Science ®Google Scholar
• ••Thorough discussion on the resistance of Can dida, suscep-tibility testing, and the correlation between in vitro resis-tance and clinical failure for mucosal and invasive disease.
   Google Scholar
• WALSH TJ: Recent advances in the treatment of sys-temic fungal infections. Methods Find. Exp. Clin. Phar-macol. (1987) 9:769–778.
   PubMed Web of Science ®Google Scholar
• VAN TYLE JH: Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy (1984) 4:343–373.
   PubMed Web of Science ®Google Scholar
• CLEARY JD, TAYLOR JW, CHAPMAN SW: Itr aeon azole in antifungal therapy. Ann. Pharmacother. (1992) 26:502–509.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, PIZZO A: Treatment of systemic fungal infec-tions: recent progress and current problems. Eur. Clin. Microbiol. Infect. Dis. (1988) 7:460–475.
   PubMed Web of Science ®Google Scholar
• SUGAR AM, LIU XP: In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. (1996) 40:1314–1316.
   PubMed Web of Science ®Google Scholar
• HARIA M, BRYSON HM, GOA KL: Itraconazole. A reap-praisal of its pharmacological properties and thera-peutic use in the management of superficial fungal infections. Drugs (1996) 51 :585–620.
   Google Scholar
• SAWYER PR, BROGDEN RN, PINDER RM eta].: Clotrima-zole: a review of its antifungal activity and therapeutic efficacy. Drugs (1975) 9:424–447.
   Google Scholar
• SUGAR AM: Use of amphotericin B with azole antifun-gal drugs: what are we doing?Antimicrob. Agents Chemo-ther. (1995) 39:1907–1912.
   PubMed Web of Science ®Google Scholar
• •Provocative position paper on the possibilities of azole-polyene combination therapies.
   Google Scholar
• CORBETT S: Intravenous modalities in the treatment of bloodborne pathogen illnesses: antibiotics, antifun-gals, and antivirals.j Intraven. Nurs. (1995) 18:S17–21.
   PubMedGoogle Scholar
• BOKEN DJ, SWINDELLS S, RINALDI MG: Fluconazole-resistant Candida albicans. Clin. Infect. Dis. (1993) 17 :1018–1021.
   PubMed Web of Science ®Google Scholar
• SHEN LL, BARANOWSKI J, FOSTEL J et al.: DNA topoi-somerases from pathogenic fungi: targets for the dis-covery of antifungal drugs. Antimicrob. Agents Chemother. (1992) 36:2778–2784.
   PubMed Web of Science ®Google Scholar
• SKOGERSON L, ENGELHARDT D: Dissimilarity in pro-tein chain elongation factor requirements between yeast and rat liver ribosomes. J. Biol. Chem. (1977) 252:1471–1475.
   PubMed Web of Science ®Google Scholar
• BELFIELD GP, TUITE MF: Translation elongation factor 3: a fungus-specific translation factor? Mol. Microbiol. (1993) 9:411–418.
   Web of Science ®Google Scholar
• DENNING DW: Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J. An-timicrob. Chemother. (1997) 40:611–614.
   PubMed Web of Science ®Google Scholar
• CASSONE A: Cell wall of pathogenic yeasts and implica-tions for antimycotic therapy. Drugs Exp. Clin. Res. (1986) 12:635–643.
   PubMedGoogle Scholar
• KURTZ MB, DOUGLAS CM: Iipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. (1997) 35:79–86.
   PubMedGoogle Scholar
• •Excellent review of the lipopeptide class of antifungal agents and a discussion of the genetics and biochemistry of glucan synthase.
   Google Scholar
• KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the t Candida species and Cryptococcus neoformans. An-timicrob. Agents Chemother. (1997) 41:1957–1960.
   PubMed Web of Science ®Google Scholar
• UZUN O, KOCAGOZ S, CETINKAYA Y eta].: In vitro activ-ity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clini-cal yeast isolates. Antimicrob. Agents Chemother. (1997) 41:1156–1157.
   Google Scholar
• VAZQUEZ JA, LYNCH M, BOIKOV D eta].: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Anti-microb. Agents Chemother. (1997) 41:1612–1614.
   Google Scholar
• NELSON PW, LOZANO-CHIU M, REX JH: In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candidaisolates: influence of as-say conditions. J. Med. Vet. Mycol. (1997) 35:285–287.
   PubMedGoogle Scholar
• ZHANEL GG, KARLOWSKY JA, HARDING GA et al.: In vi-tro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and AspergiBus species. Antimicrob. Agents Chemother. (1997) 41:863–865.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, COFFMAN S: In vitro suscepti-bilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. An-timicrob. Agents Chemother. (1997) 41 :763–766.
   PubMed Web of Science ®Google Scholar
• KURTZ MB, HEATH IB, MARRINAN J eta].: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. [Published erratum appears in Antimicrob. Agents Chemother. 1994 38(10):2516[. Antimicrob. Agents Chemother. (1994) 38:1480–1489.
   Google Scholar
• HOBAN D, KABANI A, KARLOWSKY J eta].: Evaluation of in vitro activity of a new echinocandin, LY303366 against systemic isolates of Candida spp. and Crypto-coccus neoformans. 36th Interscience Conference on An-timicrobial Agents and Chemotherapy (1996): F47.
   Google Scholar
• RENNIE R, SAND C, SMITHS: In vitro activity of antifun-gal agent LY303366 against Candida species, other yeasts, and AspergiBus species. 36th Interscience Con-ference on Antimicrobial Agents Chemotherapy (1996): F45.
   Google Scholar
• VERWEIJ PE, OAKLEY KL, MORRISSEY J eta].: Efficacy of LY-303366 against amphotericin B 'susceptible' and 'r-esistant' A. fumigatusinfection in an immunocompro-mised murine model. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997): F72.
   Google Scholar
• ZELENITSKY S, KARLOWSKY J, HOBAN D eta].: Activity of an investigational echinocandin, LY303366 against fluconazole susceptible and resistant Candida albi-cans in a multiple dose in vitro pharmacodynamic model. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997).
   Google Scholar
• MOORE CB, OAKELY KL, DENNING DW: In vitro activity of LY303366 compared with fluconazole, flucytosine, and amphotericin B against Candida spp. 37th Intersci-ence Conference on Antimicrobial Agents and Chemother-apy (1997): F67.
   Google Scholar
• ZECKNER D, BUTLER T, BOYLAN C et al.: LY 303366: ac-tivity in a rat mucocutaneous vaginal candidiasis model. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (1994): F–169.
   Google Scholar
• ZECKNER D, BUTLER T, BOYLAN C et al.: LY 303366: ac-tivity against systemic aspergillosis and histoplasmo-sis in murine models. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (1993)364.
   Google Scholar
• RAAB P, ZECKNER D, BOYLL B eta].: LY 303366: Com-parison of activity in murine models of Aspergillus fu-migatus infection. 33th Interscience Conference on Antimicrobial Agents and Chemotherapy (1994):F364.
   Google Scholar
• RAJMNA I, DESANTE K, HATCHER B eta].: LY 303366 sin-gle intravenous dose pharmacokinetics and safety in healthy volunteers. 37th Interscience Conference on Anti-microbial Agents and Chemotherapy (1997):F74.
   Google Scholar
• BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro pre-clinical evaluation studies with the echinocandin anti-fungal MK-0991 (L-743,872) [In Process Citation]. Antimicrob. Agents Chemother. (1997) 41 :2326–2332.
   PubMed Web of Science ®Google Scholar
• DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifun-gal activity of pneumocandin L-743,872 against a vari-ety of clinically important molds. Antimicrob. Agents Chemother. (1997) 41:1835–1836.
   PubMed Web of Science ®Google Scholar
• BARTIZAL K, FLATTERY A, LYNCH L eta].: In vitro pre-clinical evaluation studies with pneumocandin anti-fungal L-743,872. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F32.
   Google Scholar
• HAJDU R, PELAK B, SUNDELOF R eta].: Pharmacokinet-ics of L-743,872 in the mouse, rat, rhesus, and chim-panzee. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F–44.
   Google Scholar
• GRAYBILL JR, BOCANEGRA R, LUTHER M et al.: Treat-ment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother. (1997) 41:1937–1939.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR LK, LUTHER MF eta].: Treatment of murine disseminated candidiasis with L-743,872. Anti-microb. Agents Chemother. (1997) 41:1775–1777.
   Google Scholar
• ABRUZZO GK, FLATTERY AM, GILL CJ eta].: Evaluation of the echinocandin antifungal MK-0991 (L-743,872): ef-ficacies in mouse models of disseminated aspergillo-sis, candidiasis, and cryptococcosis [In Process Citation]. Antimicrob. Agents Chemother. (1997) 41 :2333–2338.
   Google Scholar
• ABRUZZO GK, FLATTERY AM, GILL CJ et al.: Evaluation of water soluble pneumocandin L-743,872 in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. 36th Interscience Conference on Antimi-crobial Agents and Chemotherapy (1996):F37.
   Google Scholar
• POWLES M, ANDERSON J, LIBERATOR P eta].: Efficacy of semisynthetic pneumocandin analog L-743,872 against Pneumocystis carinii in murine models. 36th Interscience Conference on Antimicrobial Agents and Che-motherapy (1996):F42.
   Google Scholar
• BERNARD EM, ISHIMARU T, ARMSTRONG D: Iipw doses of pneumocandin L-743,872 are effective prevention and treatment in an animal model of pulmonary as-p ergillosis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F39.
   Google Scholar
• BARTIZAL K, SMITH JG, GILL CJ eta].: Preclinical efficacy of MK-0991 in pancytopenic mouse models of dissemi-nated candidiasis and aspergillosis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):F–80.
   Google Scholar
• LI I, THOMAS S, GRAMPOVNIK DJ et al.: Synthesis and antifungal activities of cyclopeptamines. Novel cell wall synthesis inhibitors. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):F238.
   Google Scholar
• DEBONO M, GORDEE RS: Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. (1994) 48:471–497.
   PubMed Web of Science ®Google Scholar
• ••Discussion of the cell wall as a viable therapeutic target anda review on inhibitors specific for glucan synthase, chitin synthase, or mannan.
   Google Scholar
• GAUGHRAN JP, LAI MH, KIRSCH DR eta].: Mkkomycin Z is a specific inhibitor of Saccharomyces cerevisiae synthase isozyme Chs3 in vitro and in vivo. J. Bacte-riol. (1994) 176:5857–5860.
   Google Scholar
• HECTOR RF, ZIMMER BL, PAPPAGIANIS D: Evaluation of nikkomycins X and Z in murine models of coccidioi-domycosis, histoplasmosis, and blastomycosis. Anti-microb. Agents Chemother. (1990) 34:587–593.
   PubMed Web of Science ®Google Scholar
• CABIB E: Differential inhibition of chitin synthetases 1 and 2 from Saccharomyces cerevisiae by polyoxin D and nikkomycins. Antimicrob. Agents Chemother. (1991) 35:170–173.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Anti-microb. Agents Chemother. (1997) 41 :2026–2028.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, GIRI N: Pradimicins: a novel class of broad-spectrum antifungal compounds. Eur.j Clin. Microbiol. Infect. Dis. (1997) 16:93–97.
   PubMed Web of Science ®Google Scholar
• ••Excellent introduction to the pradimicins including theirstructures, mechanism of action, spectrum of in vitro activ-ity, in vivo efficacy and early pharmacokientic data.
   Google Scholar
• MCGINNIS MR, PASARELL L, SUTTON DA eta].: In vitro evaluation of voriconazole against some clinically im-portant fungi. Antimicrob. Agents Chemother. (1997) 41:1832–1834.
   Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of SCH-56592 and comparison with activities of am-photericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. (1997) 41:1124–1126.
   PubMed Web of Science ®Google Scholar
• RUHNKE M, SCHMIDT-WESTHAUSEN A, TRAUTMANN M: In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albi-cansisolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. (1997) 41:575–577.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MORRISSEY G, DENNING DW: Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole- f Aspergiffus fumigatus. Antimicrob. Agents Chemother. (1997) 41:1504–1507.
   PubMed Web of Science ®Google Scholar
• MURPHY M, BERNARD EM, ISHIMARU T eta].: Activity of voriconazole (UK-109,496) against clinical isolates of Aspergiffus species and its effectiveness in an experi-mental model of invasive pulmonary aspergillosis. An-timicrob. Agents Chemother. (1997) 41 :696–698.
   Google Scholar
• NAJVAR LK, CORREA A, JAMES P eta].: ZD0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans. J. Antimicrob. Chemother. (1996) 38:671–677.
   Google Scholar
• YOKOYAMA K, WANG L, MIYAJI M: SSY726, a new tria-zole antifungal agent: in vitro and in vivo evaluation. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F75.
   Google Scholar
• MATSUMOTO M, ASAOKA T, IWASA A: Efficacy of SSY726 on systemic candidosis and cryptococcosis in neutropenic mice. 36th Interscience Conference on Anti-microbial Agents and Chemotherapy (1996):F76.
   Google Scholar
• IKEDA Y, YAMAMOTO K, HIRAYAMA F: Anticryptococ-cal activity of SSY726, a new triazole antifungal agent in a murine pulmonary infection model. 36th Intersci-ence Conference on Antimicrobial Agents and Chemother-apy (1996):F77.
   Google Scholar
• ITOH K, OKONOGI K, TASAKA A eta].: TAK-187, a new antifungal triazole: synthesis and antifungal activity. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F74.
   Google Scholar
• CAILLOT D, CASASNOVAS O, BERNARD A et al.: Im-proved management of invasive pulmonary aspergil-losis in neutropenic patients using early thoracic computed tomographic scan and surgery. j Clin. On-col (1997) 15:139–147.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ S, MILATOVIC D, THIEL E: Successful treat-ment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br. J. Haematol. (1997) 97:663–665.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-SOUSA A, ALVAREZ ME, PARRA C eta].: Activity on clinical isolates of a new antifungal agent, GM 237354. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):F56.
   Google Scholar
• HERREROS E, MARTINEZ CM, ALMELA MJ et al.: In vitro activity of GM 237354 against a broad range of fungi. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):F57.
   Google Scholar
• MARTINEZ A, JIMENEZ E, AVILES P et al.: Activity of GM 237354 against murine models of systemic and oral candidiasis. 37th Interscience Conference on Antimicro-bial Agents and Chemotherapy (1997):F61.
   Google Scholar
• CLEMONS KV, STEVENS DA: Efficacy of sordarin deriva-tives GM193663, GM211676 or GM237354 in a murine model of systemic coccidiomycosis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):F62.
   Google Scholar
• DEI-CAS E, ALIOUAT EM, MULLEET C eta].: Anew antimi-crobial molecule (GM 237354) highly active against Pneumocystis carinii: in vivo studies and ultrastruc-tur al data. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):F65.
   Google Scholar
• NAJ VAR LK, BOCANEGRA RA, FOTHERGILL AW eta].: New sordaricin antifungal drugs active in murine histoplas-mosis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):F63.
   Google Scholar
• URITANI M, NAKANO K, AOKI Y eta].: Polyamino acids that inhibit the interaction of yeast translational elon-gation factor-3 (EF-3) with ribosomes. j Biochem. (1994) 115:820–824.
   Google Scholar
• FAVRE B, RYDER NS: Differential inhibition of fungal and mammalian squalene epoxidases by the ben-zylamine SDZ SBA 586 in comparison with the al-lylamine terbinafine. Arch. Biochem. Biophys. (1997) 340:265–269.
   PubMed Web of Science ®Google Scholar
• BARRETT-BEE K, DIXON G: Ergosterol biosynthesis in-hibition: a target for antifungal agents. Acta Biochim. Pol. (1995) 42:465–479.
   PubMed Web of Science ®Google Scholar
• DYKSTRA CC, MCCLERNON DR, ELWELL LP et al.: Selec-tive inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells. Antimicrob. Agents Chemother. (1994) 38:1890–1898.
   PubMed Web of Science ®Google Scholar
• PERFECT JR: Fungal virulence genes as targets for anti-fungal chemotherapy. Antimicrob. Agents Chemother. (1996) 40:1577–1583.
   PubMed Web of Science ®Google Scholar
• SLAUCH JM, MAHAN MJ, MEKALANOS JJ: In vivo expres-sion technology for selection of bacterial genes spe-cifically induced in host tissues. Methods Enzymol. (1994) 235:481–492.
   PubMed Web of Science ®Google Scholar
• MAHAN MJ, TOBIAS JW, SLAUCH JM et al.: Antibiotic-based selection for bacterial genes that are specifically induced during infection of a host. Proc. Natl. Acad. Sci. USA (1995) 92:669–673.
   PubMed Web of Science ®Google Scholar
• WANG J, MUSHEGIAN A, LORY S eta].: large-scale isola-tion of candidate virulence genes of Pseudomonas ae-ruginosa by in vivo selection. Proc. Nat]. Acad. Sci. USA (1996) 93:10434–10439.
   Google Scholar
• HEITHOFF DM, CONNER CP, HANNA PC eta].: Bacterial infection as assessed by in vivo gene expression. Proc. Natl. Acad. Sci. USA (1997) 94:934–939.
   Google Scholar
• RAINEY PB, HEITHOFF DM, MAHAN MJ: Single-step con-jugative cloning of bacterial gene fusions involved in microbe-host interactions. Mol. Gen. Genet. (1997) 256:84–87.
   PubMedGoogle Scholar